We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

No exit

5 November 2018 By Reynolds Holding

If Boston Scientific manages to nix its $275 mln deal with Channel Medsystems, it’ll be only the second Delaware case of a buyer able to walk after a material adverse change. More likely the courts will toss both cases at trial or on appeal. The upside should be clearer rules.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)